According to the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC, biomarker tests for EGFR mutation, ALK rearrangement, ROS1 rearrangement, BRAF V600E mutation, NTRK1/2/3 gene fusion, METex14 skipping mutation, RET rearrangement, and PD-L1 expression are recommended for all LUAD patients and partially recommended for LUSC patients. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.